Navigation Links
All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
Date:5/26/2011

PRINCETON, N.J., May 26, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's (NYSE: BMY) NS5A replication complex inhibitor, for the treatment of chronic hepatitis C (HCV).  This trial is the result of a clinical collaboration agreement between Pharmasset and Bristol-Myers Squibb announced in January 2011.

"We are happy to announce the initiation of this important combination trial," stated William Symonds, Pharmasset's Senior Vice President of Clinical Pharmacology and Translational Medicine. "Recent data from Bristol-Myers Squibb's combination study demonstrated that individuals with HCV can be cured without the traditional interferon and ribavirin, but only if two potent DAAs are used and drug resistance is avoided. We believe Pharmasset's nucleotide analogs have demonstrated potent antiviral activity and a high barrier to resistance and therefore have the potential to be the future backbone of interferon-free treatment."

About the Trial

This Phase 2a trial is planned to enroll approximately 84 patients with chronic HCV genotypes 1, 2 or 3 who have not been treated previously. The primary endpoint of the trial is sustained virologic response (SVR). The trial will be conducted in the U.S. Subjects will be randomized equally across each of the following arms:

  • PSI-7977 400mg QD for 7 days, then add BMS-790052 60mg QD for further 23 weeks in genotype 1 subjects;
  • PSI-7977 400mg QD for 7 days, then add BMS-790052 60mg QD for further 23 weeks in genotype 2 or 3 subjects;
  • PSI-7977 400mg QD and BMS-790052 60mg QD for 24 weeks in g
    '/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
4. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
5. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
6. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
7. Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
8. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
9. New Interim Data About Combination Oral Contraceptives
10. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
11. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Israel , May 23, 2013 ... BrainTech Israel 2013 , Israel,s 1 ... on October 14 th -15 th in ... most innovative city in the world by the ... Nation." BrainTech Israel 2013 will showcase the latest ...
(Date:5/23/2013)... , May 23, 2013  Datameer announced today ... enable data discovery on their big data platform. ... tools they need to quickly and easily visualize ... A Fortune 19 company, Cardinal Health is ... It provides pharmaceuticals and medical products to more ...
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Cardinal Health Selects Datameer for Healthcare Data Discovery 2
... Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today announced ... on Tuesday, November 1, 2011 at 4:30 p.m. Eastern Time/1:30 ... a business and financial update and review third quarter 2011 ... may be accessed from the Investors section of the Jazz ...
... Genprex, Inc. announced today that it will be presenting ... in San Francisco.   Greg Heinlein , Chief Operating and Financial ... Investor Forum , on October 25 starting at 11 a.m. PDT ... will be made available on the company,s website under the News ...
Cached Medicine Technology:Genprex Presenting at 10th Annual BIO Investor Forum 2
(Date:5/23/2013)... 23, 2013) Treating pediatric leukemia patients with a ... dose during initial treatment may result in high survival ... the results of a study published online ... of the American Society of Hematology (ASH). ... common form of leukemia in children, is a blood ...
(Date:5/23/2013)... Henry Ford Hospital found "substantial evidence" that a regenerative ... could hold the key to better functional recovery by ... to those who suffer stroke, the leading cause of ... some ability to voluntarily use their hands and other ... one side of their bodies, while a substantial number ...
(Date:5/23/2013)... Alachua, FL (PRWEB) May 23, 2013 ... leading regenerative medicine company focused on the commercialization ... reconstruction and regeneration, today announced that the Company ... $1.1 million grant, for which AxoGen’s portion is ... Programs administrated by the U.S. Department of Defense ...
(Date:5/23/2013)... May 23, 2013 Hile Design LLC ... firm was awarded a Silver Creative Award at the ... The winning entry was for its “Open Doors” animation ... of Show” in the 2013 District 6 ADDY Awards ... The Summit Creative Award recognizes and celebrates the creative ...
(Date:5/23/2013)... 2013 Registered Dietitian and Founder of ... today on Tatalou.com offering helpful tips for travelers who ... titled “ How to Stay Healthy While Traveling ,” ... sanitizer, when it’s safe to drink the water when ... importance of staying hydrated and how taking health supplements ...
Breaking Medicine News(10 mins):Health News:Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity 2Health News:Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity 3Health News:Regenerating spinal cord fibers may be treatment for stroke-related disabilities 2Health News:Regenerating spinal cord fibers may be treatment for stroke-related disabilities 3Health News:AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense 2Health News:AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense 3Health News:How to Stay Healthy While Traveling 2
... ... USA offers two for one deal on summits. Also book your room before the ... ... Biopolymers Symposium 2009 conference and exhibit, taking place at the Embassy Suites Downtown Lakefront, in ...
... , , , ... Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn,s Guide ... the Ad dressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, ... severe plaque psoriasis who have not allowed the condition to inhibit their ...
... greater alcohol consumption, study shows , WEDNESDAY, Sept. 2 (HealthDay ... intoxicated students and more health and safety problems, new research ... and the results can be injury, violence and even death. ... at college bars and found that cheap drinks come with ...
... before 65, study finds, many younger patients not getting ... could be affecting Americans earlier in life than ever ... longer an affliction of old age," said lead researcher ... neurology and investigator for the Cognitive Rehabilitation Research Group ...
... , , MURRIETA, Calif., ... its ABTTC Inc. division, provides drug and alcohol rehabilitation and ... levels of accreditation, announced today that its co-founder and CEO, ... Company,s recent successes, management team and shareholder relations. , ...
... , Pfizer to Pay $2.3 Billion ... Sept. 2 American pharmaceutical giant Pfizer Inc. and its subsidiary ... pay $2.3 billion, the largest health care fraud settlement in the ... liability arising from the illegal promotion of certain pharmaceutical products, the ...
Cached Medicine News:Health News:Biopolymers Symposium 2009 Offers Two for One Deal: Attend Retailers Scorecard Seminar and Attend the EcoLabeling Summit Free 2Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 2Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 3Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 4Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 5Health News:College Students Get More Drunk When Drinks Are Cheap 2Health News:Stroke May Be Striking at a Younger Age 2Health News:Stroke May Be Striking at a Younger Age 3Health News:Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed 2Health News:Justice Department Announces Largest Health Care Fraud Settlement in its History 2Health News:Justice Department Announces Largest Health Care Fraud Settlement in its History 3Health News:Justice Department Announces Largest Health Care Fraud Settlement in its History 4Health News:Justice Department Announces Largest Health Care Fraud Settlement in its History 5Health News:Justice Department Announces Largest Health Care Fraud Settlement in its History 6
... The White Sun light source offers the industry ... Kelvin color temperature at a lower price. A ... White Sun to be used with Olympus, Storz, ... light output LED and re-settable bulb timer. The ...
... The NGAL ELISA Kit is intended for ... (e.g. plasma, serum, urine), tissue extracts or ... dramatically increased, especially in urine, as early ... in ongoing renal repair processes. NGAL expression ...
... Light Head is clearly the favorite for ... 36-inch arms, the dual light heads rotate ... stability, providing unlimited positioning. Engineered construction prevents ... ranging from minimally invasive through trauma to ...
... offers all the performance of a major surgical ... use in Outpatient Settings, Minor Procedure Rooms, C-Section, ... single lights either side of the OR table ... General OR when combining Flat Screen LCD Monitors ...
Medicine Products: